RFID in Pharmaceuticals Market Report 2028: Potential Effect on Upcoming Future Growth, Competitive

Future Market Insights (FMI), in its new study, finds that the radio-frequency identification (RFID) in pharmaceuticals market was valued at over US$ 950 Mn in 2018, and is estimated to register a Y-o-Y growth at approximately 10% in 2019. Prospects remain remarkable for the RFID in pharmaceuticals industry, as efficiency-led actions of players continue to enhance the reliability and accuracy of their business operations.

The study finds that drug tracing system remains the most lucrative application of RFID in pharmaceutical industry, accounting for approximately 60% sales. Efforts of the FDA, in collaboration with pharmaceutical suppliers, to maintain a secure drug supply in the wake of rising counterfeit drugs prevalence, has encouraged the pharmaceutical industry to use RFID in combination with the electronic product code (EPC) for real-time tracking, tracing, and authentication of drugs.

According to the study, such preventative measures against infiltration of counterfeit drugs are likely to have a positive economic influence on legitimate companies, who are now focusing on the deployment of anti-counterfeiting solutions. Focus of the organized players in the pharmaceutical sector to safeguard authenticity of their products, while creating moats for counterfeiters, will continue to favour growth of the RFID in pharmaceutical market.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-9508

Chipless RFID Sales Remain Over 2X of Chipped RFID

According to the study, chipless RFIDs continue to gain robust attractiveness in the pharmaceutical industry, as they eliminate the hardware-related challenges associated with their chipped counterparts. Additionally, RFIDs without ICs allude at significant cost reduction of the component, in turn complementing their development and demand on a wide scale. However, complexities linked with designing and development of chipless RFID, such as data transmission and encoding, continue to sustain the demand for the chipped RFID to a certain extent. The study finds that sales of chipless RFID will remain over 2X that of the chipped RFID in 2019.

The study expects RFID reader to remain the core component in the RFID in pharmaceutical market, with growing focus of pharma suppliers on effective identification of products prior to their collection, storage and shipping. Gains in the RFID in pharmaceutical market will remain complemented by sales of RFID tags, with revenues in 2018 accounting for over one-third market share.

Adoption Remains High among Drug Manufacturers

Application diversity of RFID in pharmaceutical industry has led its adoption among a wide range of end-users that range from drug manufacturers and drug wholesalers, to hospitals and clinics. The report estimates drug manufacturers to account for leading shares of the RFID in pharmaceutical market, who are constantly emphasizing on ensuring the authenticity of their products in the market. Adoption is expected to witness high-growth among drug wholesalers and hospitals and clinics, which collectively account for over two-fifth share of the market.

Request to View TOC @ https://www.futuremarketinsights.com/askus/rep-gb-9508

The study states that North America will remain the leading market for RFID in pharmaceutical, with Europe following the suit. Supremacy of developed economies in the RFID in pharmaceutical market is significantly attributed to stringent standards & regulations implemented for serialization, and relative greater prevalence of OTC and generic drugs in these regions. Additionally, focus of players in developed markets remains strong on brand protection, and preventing packaging-related product recalls, which in turn augurs well for growth of the RFID in pharmaceutical market.

Persistence Market Research (Pmr) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.